Cargando…
EPH75 COVID-19 Vaccine Breakthrough Infections in the United States, By Race
Autores principales: | Liu, M, Wong, AC, McPheeters, JT, Dixon, R, Madge, V, Basra, G, Sachdev, A, Veeranki, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232717/ http://dx.doi.org/10.1016/j.jval.2022.04.828 |
Ejemplares similares
-
P13 Risk of COVID-19 Vaccine Breakthrough Infection in Fully Vaccinated Patients with Multiple Comorbid Conditions in the United States
por: Liu, M., et al.
Publicado: (2022) -
RWD118 Long-Term Neurologic Sequelae Among Patients with Varying COVID-19 Severity: An Administrative Claims Database Analysis
por: Dhangar, I., et al.
Publicado: (2023) -
RWD81 Long-Term Metabolic Sequelae of COVID-19, By Severity Levels
por: Dhangar, I., et al.
Publicado: (2023) -
POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States
por: Madge, V, et al.
Publicado: (2022) -
Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)